Descriptive statistics of the studied biomarkers in different patient groups
| Patient group . | Sex . | n . | Age, median (IQR), y . | Iron blood marker median (IQR) . | |||||
|---|---|---|---|---|---|---|---|---|---|
| Ferritin, μg/L . | TSAT, % . | sTfR, mg/L . | Transferrin, g/L . | Hemoglobin, g/L . | MCV, fL . | ||||
| All | Both | 6610 | 66 (55-75) | 180 (68-458) | 23 (15-34) | 3.7 (2.6-5.6) | 2.2 (1.8-2.7) | 116 (100-133) | 91 (87-97) |
| Female | 3065 | 66 (54-76) | 127 (46-360) | 21 (14-31) | 3.8 (2.7-5.9) | 2.3 (1.9-2.8) | 113 (98-130) | 91 (86-96) | |
| Male | 3545 | 67 (56-75) | 234 (100-566) | 25 (16-35) | 3.6 (2.6-5.3) | 2.2 (1.8-2.6) | 119 (102-137) | 92 (87-97) | |
| MPN | Female | 391 | 65 (52-75) | 59 (25-112) | 23 (13-30) | 4.0 (2.8-6.8) | 2.7 (2.4-3) | 137 (124-151) | 89 (85-93) |
| Male | 353 | 63 (54-71) | 108 (33-202) | 24 (14-34) | 3.4 (2.7-5.3) | 2.5 (2.3-2.9) | 150 (128-167) | 89 (85-93) | |
| MDN | Female | 444 | 65 (51-76) | 138 (60-404) | 28 (18-39) | 3.3 (2.4-4.7) | 2.4 (2.1-2.7) | 116 (98-133) | 91 (87-98) |
| Male | 493 | 67 (56-76) | 292 (128-574) | 30 (21-42) | 3.8 (2.8-5.4) | 2.3 (1.9-2.6) | 119 (100-143) | 93 (88-99) | |
| HM | Female | 957 | 68 (59-76) | 253 (95-626) | 21 (15-33) | 3.7 (2.5-5.9) | 2.0 (1.7-2.4) | 106 (94-120) | 93 (88-97) |
| Male | 1220 | 67 (57-75) | 378 (132-939) | 27 (17-39) | 3.7 (2.5-6.1) | 2.0 (1.7-2.4) | 111 (97-128) | 93 (88-98) | |
| non-IDA | Female | 125 | 60 (43-74) | 256 (70-677) | 29 (22-64) | 4.8 (2.5-7.2) | 2.1 (1.7-2.7) | 96 (83-110) | 95 (89-100) |
| Male | 103 | 58 (46-72) | 388 (172-785) | 29 (22-42) | 4.3 (2.3-5.8) | 2.0 (1.7-2.3) | 103 (88-124) | 96 (89-101) | |
| Others | Female | 1236 | 66 (51-76) | 114 (36-323) | 19 (10-27) | 4.0 (2.8-5.9) | 2.3 (1.9-2.8) | 112 (99-127) | 90 (85-95) |
| Male | 1493 | 68 (57-77) | 220 (99-512) | 23 (14-33) | 3.5 (2.6-4.8) | 2.2 (1.7-2.6) | 119 (103-133) | 91 (87-96) | |
| Patient group . | Sex . | n . | Age, median (IQR), y . | Iron blood marker median (IQR) . | |||||
|---|---|---|---|---|---|---|---|---|---|
| Ferritin, μg/L . | TSAT, % . | sTfR, mg/L . | Transferrin, g/L . | Hemoglobin, g/L . | MCV, fL . | ||||
| All | Both | 6610 | 66 (55-75) | 180 (68-458) | 23 (15-34) | 3.7 (2.6-5.6) | 2.2 (1.8-2.7) | 116 (100-133) | 91 (87-97) |
| Female | 3065 | 66 (54-76) | 127 (46-360) | 21 (14-31) | 3.8 (2.7-5.9) | 2.3 (1.9-2.8) | 113 (98-130) | 91 (86-96) | |
| Male | 3545 | 67 (56-75) | 234 (100-566) | 25 (16-35) | 3.6 (2.6-5.3) | 2.2 (1.8-2.6) | 119 (102-137) | 92 (87-97) | |
| MPN | Female | 391 | 65 (52-75) | 59 (25-112) | 23 (13-30) | 4.0 (2.8-6.8) | 2.7 (2.4-3) | 137 (124-151) | 89 (85-93) |
| Male | 353 | 63 (54-71) | 108 (33-202) | 24 (14-34) | 3.4 (2.7-5.3) | 2.5 (2.3-2.9) | 150 (128-167) | 89 (85-93) | |
| MDN | Female | 444 | 65 (51-76) | 138 (60-404) | 28 (18-39) | 3.3 (2.4-4.7) | 2.4 (2.1-2.7) | 116 (98-133) | 91 (87-98) |
| Male | 493 | 67 (56-76) | 292 (128-574) | 30 (21-42) | 3.8 (2.8-5.4) | 2.3 (1.9-2.6) | 119 (100-143) | 93 (88-99) | |
| HM | Female | 957 | 68 (59-76) | 253 (95-626) | 21 (15-33) | 3.7 (2.5-5.9) | 2.0 (1.7-2.4) | 106 (94-120) | 93 (88-97) |
| Male | 1220 | 67 (57-75) | 378 (132-939) | 27 (17-39) | 3.7 (2.5-6.1) | 2.0 (1.7-2.4) | 111 (97-128) | 93 (88-98) | |
| non-IDA | Female | 125 | 60 (43-74) | 256 (70-677) | 29 (22-64) | 4.8 (2.5-7.2) | 2.1 (1.7-2.7) | 96 (83-110) | 95 (89-100) |
| Male | 103 | 58 (46-72) | 388 (172-785) | 29 (22-42) | 4.3 (2.3-5.8) | 2.0 (1.7-2.3) | 103 (88-124) | 96 (89-101) | |
| Others | Female | 1236 | 66 (51-76) | 114 (36-323) | 19 (10-27) | 4.0 (2.8-5.9) | 2.3 (1.9-2.8) | 112 (99-127) | 90 (85-95) |
| Male | 1493 | 68 (57-77) | 220 (99-512) | 23 (14-33) | 3.5 (2.6-4.8) | 2.2 (1.7-2.6) | 119 (103-133) | 91 (87-96) | |
HM, hematologic malignancy; IQR, interquartile range; MDN, myelodysplastic neoplasia; MPN, myeloproliferative neoplasia.